PGRMC1 and breast carcinoma: Normal MCF10A breast cells, as well as ZR-75-1 and MDA-MB-468 breast cancer cells, were treated with a selective PGRMC1 inhibitor (AG-205) at different concentrations (10–100 μM) for 24 h to determine the optimal dose for studying the PGRMC1 mechanism of action.